secwatch.observer — SEC 8-K summary
======================================

Issuer:     HeartSciences Inc. (HSCS)
CIK:        0001468492
Form:       8-K
Filed at:   2025-05-19T23:59:59+00:00
Accession:  0000950170-25-074598
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq grants HeartSciences extension to Sept 15, 2025 for equity rule; Q3 cash $2.6M, equity $1.8M
--------------------------------------------------------------------------------

- Nasdaq extension to Sept 15, 2025 to regain $2.5M minimum stockholders' equity; delisting if not met by Oct 31, 2025 10-Q filing.
- Q3 FY2025 ended Jan 31, 2025: no revenue, cash $2.6M, shareholders' equity $1.8M.
- MyoVista wavECG device clinical validation nearing completion; FDA submission expected first half calendar 2025.
- Low ejection fraction algorithm pre-validation with Rutgers; aim for FDA submission in second half 2025.
- CMS 2025 OPPS final rule includes AI-ECG reimbursement effective Jan 2025, enabling payment upon commercial launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468492/000095017025074598/0000950170-25-074598-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468492/000095017025074598/hscs-20250514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-074598

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer